Payment overview · 2025
General Payments
$635.90
17 reported records · 12 companies
Healthcare provider profile · identity verified
Bridget Beier, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · BETHEL PARK, PA · NPI 1538376736
Verified facts
What the public records show
CMS Open Payments records show Bridget Beier, DO received $635.90 in general payments during 2025 across 17 reported records.
Amgen Inc. accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 313 claims for Synthroid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $194.21 | 30.5% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $92.86 | 14.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $81.47 | 12.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.42 | 9.7% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $33.83 | 5.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.72 | 4.8% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $29.97 | 4.7% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $28.06 | 4.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.32 | 3.8% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $22.39 | 3.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.63 | 3.1% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $17.02 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $635.90 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $194.21 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $92.86 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $61.42 | 3 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $34.43 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $33.83 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $30.72 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $29.97 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 313 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
313 | 89 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1200 | 323 |
| Ozempic | Semaglutide | 669 | 132 |
| Mounjaro | Tirzepatide | 430 | 109 |
| Jardiance | Empagliflozin | 351 | 83 |
| Metformin Hcl | Metformin Hcl | 339 | 103 |
| Synthroid | Levothyroxine Sodium | 313 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 310 | 96 |
| Metformin Hcl Er | Metformin Hcl | 295 | 91 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 287 | 93 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 282 | 108 |
| Glimepiride | Glimepiride | 199 | 63 |
| Tresiba Flextouch U-200 | Insulin Degludec | 149 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 45 |
| Novolog Flexpen | Insulin Aspart | 125 | 40 |
| Humalog Kwikpen U-100 | Insulin Lispro | 124 | 50 |
| Lisinopril | Lisinopril | 116 | 40 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 42 |
| Methimazole | Methimazole | 110 | 27 |
| Alendronate Sodium | Alendronate Sodium | 95 | 35 |
| Tradjenta | Linagliptin | 80 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 77 | 30 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | 21 |
| Losartan Potassium | Losartan Potassium | 63 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 62 | 18 |
| Cinacalcet Hcl | Cinacalcet Hcl | 51 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 15 |
| Gabapentin | Gabapentin | 47 | 17 |
| Glipizide Er | Glipizide | 43 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 43 | 13 |
| Novolog | Insulin Aspart | 41 | 11 |
| Glipizide | Glipizide | 39 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 39 | 16 |
| Calcitriol | Calcitriol | 36 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 36 | 19 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Repaglinide | Repaglinide | 33 | 14 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 32 | 18 |
| Hydrocortisone | Hydrocortisone | 32 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Simvastatin | Simvastatin | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | 12 |
| Unithroid | Levothyroxine Sodium | 26 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 22 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 16 | suppressed |
| Cabergoline | Cabergoline | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 14 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $635.90 · 17 records | Amgen Inc. | CRENESSITY, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, General - Pain Management, Intracept, REZDIFFRA, SYNTHROID, TWIIST, TZIELD, Tymlos, WaveWriter Alpha Prime 16, XYOSTED, t:slim X2 Insulin Pump with Control-IQ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Synthroid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error